Oncolytics Biotech Inc ONCY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 07/23/21 EDT
2.51quote price arrow down-0.03 (-1.18%)
Volume
171,500
52 week range
1.52 - 4.83

...

Loading . . .
  • Open2.60
  • Day High2.60
  • Day Low2.46
  • Prev Close2.54
  • 52 Week High4.83
  • 52 Week High Date04/08/21
  • 52 Week Low1.52
  • 52 Week Low Date09/04/20

Key Stats

  • Market Cap132.45M
  • Shares Out52.77M
  • 10 Day Average Volume0.26M
  • Dividend-
  • Dividend Yield-
  • Beta2.79
  • YTD % Change5.46

KEY STATS

  • Open2.60
  • Day High2.60
  • Day Low2.46
  • Prev Close2.54
  • 52 Week High4.83
  • 52 Week High Date04/08/21
  • 52 Week Low1.52
  • 52 Week Low Date09/04/20
  • Market Cap132.45M
  • Shares Out52.77M
  • 10 Day Average Volume0.26M
  • Dividend-
  • Dividend Yield-
  • Beta2.79
  • YTD % Change5.46

RATIOS/PROFITABILITY

  • EPS (TTM)-0.54
  • P/E (TTM)-4.67
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-20.215M
  • ROE (MRQ)-86.16%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)1.40%

EVENTS

  • Earnings Date08/06/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oncolytics Biotech Inc

There is no recent news for this security.

Profile

MORE
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the...
Wayne Pisano
Chairman
Matthew Coffey Ph.D.
President
Kirk Look
Chief Financial Officer
Allison Hagerman
Vice President
Address
1167 Kensington Cres Nw Suite 210
Calgary Alberta Canada T2n 1X7
Calgary, AB
00000
Canada